Answers are grounded in this paper and cite their sources.
Cancer immunotherapy is a promising way to eliminate tumor cells by using the patient's own immune system. Selecting the appropriate animal models to develop or validate preclinical immunotherapeutic trials is now an important aspect of many cancer research programs. Here we discuss the advantages and limitations of using genetically engineered immunodeficient mouse models, patient-derived xenografts (PDXs), and humanized mouse models for developing and testing immunotherapeutic strategies.
No takes yet. Share an insight, caveat, or question.
Choi et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: